

# Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice

Carrie M. Hersh, DO, Haleigh Harris, BA, Devon Conway, MD, and Le H. Hua, MD

*Neurology: Clinical Practice* Month 2020 vol. 00 no. 00 1-13 doi:10.1212/CPJ.0000000000000809

## Correspondence

Carrie M. Hersh  
herhc@ccf.org

## Abstract

### Objective

To assess the real-world comparative effectiveness of switching from natalizumab (NTZ) to a moderate-efficacy (Mod) disease-modifying therapy (DMT) vs high-efficacy therapy (HET) in patients with multiple sclerosis (MS).

### Methods


Patients discontinuing NTZ at two MS centers (n = 556) who switched to Mod DMT (n = 270) vs HET (n = 130) were assessed using propensity score (PS) weighting. PS model covariates included demographics and baseline clinical and MRI characteristics. All outcomes were reported as Mod DMT vs HET.

### Results

Of the patients included in the study, 48.6% switched to Mod DMT (dimethyl fumarate, n = 130; fingolimod, n = 140) vs 23.4% who switched to HET (ocrelizumab, n = 106; rituximab, n = 17; alemtuzumab, n = 7). Within the first 6 months post-NTZ, switchers to Mod DMT experienced comparable relapses (odds ratio [OR] = 1.36, 95% confidence interval [CI] [0.72–1.66], p = 0.724), although they had increased MRI activity on treatment (OR = 2.59, 95% CI [1.09–3.57], p = 0.037). By 24 months post-NTZ, there was no difference in the annualized relapse rate (OR = 1.44, 95% CI [0.69–1.59], p = 0.334) or time to first clinical relapse (HR = 2.12, 95% CI [0.87–5.17], p = 0.090), although switchers to Mod DMT had higher gadolinium-enhancing (GdE) lesions (OR = 3.62, 95% CI [1.56–5.21], p = 0.005), earlier time to first GdE lesion (HR = 6.67, 95% CI [2.06–9.16], p = 0.002), lower proportion with the absence of disease activity (OR = 0.41, 95% CI [0.21–0.71], p = 0.004), and higher risk of disability progression on T25FW (OR = 1.83, 95% CI [1.06–3.02], p = 0.043) and 9-HPT (OR = 1.81, 95% CI [1.05–3.56], p = 0.044).

### Conclusion

Patients switching from NTZ to Mod DMT vs HET were at relatively increased risk of disease activity within the first 6 months of NTZ withdrawal that was sustained at 24 months, yielding greater disability progression.



Lou Ruvo Center for Brain Health (CMH, HH, LHH), Cleveland Clinic, Las Vegas, NV; and Mellen Center for Multiple Sclerosis Treatment and Research (DC), Cleveland Clinic, Cleveland, OH.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](https://www.neurology.org/cp).

The Article Processing Charge was funded by the Cleveland Clinic.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Natalizumab (NTZ) is a high-efficacy disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS).<sup>1–3</sup> In clinical practice, long-term use of NTZ is limited by potential safety risks, including progressive multifocal leukoencephalopathy (PML),<sup>4,5</sup> that can be reduced by switching to a different DMT. However, the transition between NTZ and alternative therapies poses additional risks because disease reactivation can occur upon NTZ discontinuation in the form of relapses and/or gadolinium-enhancing (GdE) lesions.<sup>6–9</sup> The risk of rebound disease-activity that is worse compared to the pre-NTZ period-increases with longer NTZ washout periods > 3 months<sup>10,11</sup> and by switching to an alternative therapy with lower efficacy.<sup>12</sup> Many studies investigated the effect of switching from NTZ to a different DMT in high-risk PML populations.<sup>10–23</sup> However, consensus is still lacking in regard to DMT sequencing following NTZ cessation. A paucity of data is available that directly compare disease activity head to head across different DMT switching paradigms.

Real-world studies are therefore needed to investigate the effects of various post-NTZ sequencing strategies on both early and longer-term MS disease activity and disability progression. Published data demonstrated that patients de-escalating therapy from NTZ to a lower-efficacy DMT (e.g., glatiramer acetate, interferon beta, and teriflunomide) are at risk of rebound or breakthrough disease activity.<sup>12,18,20</sup> However, patients may fare better by switching to a moderate DMT (Mod DMT) or high-efficacy therapy (HET).

We sought to fill an important knowledge gap by comparing the effectiveness of switching from NTZ to a Mod DMT vs another HET on MS outcomes in a clinical practice cohort at 6 months and 24 months using propensity score (PS)-adjusted methods.<sup>24</sup> In the present study, we defined Mod DMT as treatment with either fingolimod or dimethyl fumarate, based on equivalent clinical and MRI outcome measures derived from various comparative effectiveness studies.<sup>25–30</sup> We defined HET as treatment switch to ocrelizumab, rituximab, or alemtuzumab.

## Methods

### Standard protocol approvals, registrations, and patient consents

This study was approved by the Institutional Review Board at the Cleveland Clinic.

### Patient population

We conducted a retrospective observational study of patients with MS treated at the Cleveland Clinic Lou Ruvo Center for Brain Health (LRCBH) and Cleveland Clinic Mellen Center who discontinued NTZ between December 2005 and January 2018 and switched either to a Mod DMT or another HET. Patients were identified through the TOUCH® prescribing program database. All patients included in the study were previously diagnosed with MS by a Cleveland Clinic MS specialist at the LRCBH or the Mellen Center.

## Data collection

All patients who switched from NTZ to a Mod DMT or HET and had 6-month and 24-month data available were identified. Baseline and outcome data were collected from the electronic medical record (EMR). To adequately capture baseline disease characteristics important for determining treatment allocation between the two therapeutic paradigms, we included covariates derived from the EMR data in the 12 months before NTZ exposure and within 6 months before NTZ discontinuation. These data were confirmed by an MS clinician before they were included in the data set. The study adjusted for NTZ washout duration >3 months to lower the risk of disease rebound as a potential confounder.

Demographics and clinical, radiographic, laboratory, and patient-reported outcome (PRO) measures were collected from the EMR. Follow-up assessments (e.g., clinician visits, MRI frequency, and protocols) did not differ between the groups. Clinical relapses—identified retrospectively in the patients' charts—were designated by the treating neurologist and defined as new or worsening MS symptoms lasting greater than 24 hours without a coexisting fever or illness. The timed 25-foot walk (T25FW)<sup>31</sup> and 9-hole peg test (9-HPT)<sup>32</sup> were measured by the treating health care providers as part of routine clinical practice. The number of new T2-hyperintense and GdE brain MRI lesions were manually counted by Cleveland Clinic neuroradiologists. Neuroradiologic data at 6-month follow-up were compared with brain MRIs 6 months before NTZ discontinuation, and 24-month neuroradiologic data were compared with brain MRIs within 12 months of initiating the switched DMT. To assess the patient experience, PRO measures, such as the Patient Health Questionnaire-9 (PHQ-9)<sup>33</sup> and Performance Scale,<sup>34</sup> were also collected. We stored collocated information in an encrypted database using a password-protected Excel Spreadsheet on secure Cleveland Clinic servers.

## Statistical analysis

Data were imported for analysis into R version 3.5.2.<sup>35</sup> The majority of covariates incorporated into the PS model were missing in <10% of patients. However, some covariates (e.g., baseline MRI data and JC virus antibody status) were missing in >10% of patients. We used the same approach as in our previously conducted studies to account for missingness patterns in the PS.<sup>25,27</sup>

Analyses were conducted in both an intention-to-treat (ITT) model and on-treatment (“per protocol”) as a sensitivity analysis for those switching from NTZ to their respective DMT strategy (Mod DMT or HET) by 6- and 24-month follow-up. The primary outcome was the annualized relapse rate ratio (ARR ratio; Mod DMT vs HET) at 24 months. The ARR was calculated by dividing the total number of relapses by the total number of person-years at risk. Secondary outcome measures included the time to first relapse, time to first GdE lesion, and proportions with new T2-hyperintense lesions, GdE lesions, MRI disease activity (a composite outcome measure defined as the proportion of patients with new T2-hyperintense lesions

and/or GdE lesions), absence of disease activity (a composite outcome measure defined as freedom from clinical relapses and MRI disease activity), and 20% worsening on the T25FW and 9-HPT.<sup>25,26,32</sup>

The PS was built as a logistic regression model to calculate the likeliness of switching from NTZ to Mod DMT, as opposed to HET, using a priori selected covariates (table 1). A PS was calculated for each patient and subsequently used in an Average Treatment effect on the Treated (ATT) weighting model to derive a sample of patients who were similar at baseline except for their allocated treatment paradigm. This approach reduced the effect of indication bias on our comparisons of NTZ switch to Mod DMT vs HET while still retaining information from all patients. Owing to different sample sizes across the two cohorts, a PS matching technique was not used because a large selection of patients would have remained unmatched, consequently introducing another selection bias into the PS model.<sup>24</sup> Before deriving conclusions on treatment effect differences between our groups of interest, we selected PS weighting on the basis of a more complete balance across the variables included in our PS model between the two cohorts.

Similar to previous studies,<sup>25,27</sup> the strength of the PS model was assessed by how well it balanced the two groups, as determined by comparing the standardized differences across the means of the covariates before and after PS adjustment. In this study, we determined excellent covariate balance as achieving an absolute standardized difference of <10% on the means of the covariates across the two therapeutic strategies. Before ATT weighting, unadjusted outcome measures were estimated using Pearson  $\chi^2$  tests for categorical data and *t* tests for continuous data. After ATT weighting, conditional logistic regression models were used to calculate odds ratio (OR) estimates for binary outcomes and Cox proportional hazards models and Kaplan-Meier survival curves to obtain survival end points. The ARR was analyzed using a Poisson regression model. Odds and hazards ratios were measured as those who switched from NTZ to a Mod DMT compared with patients who switched to HET. The primary outcome measure (ARR ratio) was based on a two-tailed test of statistical significance with  $\alpha = 0.05$ . Assuming 80% power with a total sample size of 400 patients, the minimum detectable effect size was determined to be 0.26.

## Data availability

Anonymized data can be shared at the request of qualified investigators for purposes of replicating procedures and results.

## Results

### Baseline characteristics

In the original cohort, 556 patients from the Cleveland Clinic LRCBH and the Mellen Center discontinued NTZ between December 2005 and January 2018 (figure 1). The majority of patients withdrew from NTZ due to increased PML risks ( $n = 305$ , 54.9%). Of those who had 24-month follow-up data available for review, a total of 270 patients switched to Mod

DMT (fingolimod  $n = 140$ , dimethyl fumarate  $n = 130$ ), and 130 patients transitioned to HET (ocrelizumab  $n = 104$ , rituximab  $n = 18$ , and alemtuzumab  $n = 18$ ).

Demographics and baseline disease characteristics are presented in table 1. The majority of patients in our cohort had relapsing-remitting MS at the time of natalizumab exposure (Mod DMT = 95.9%, HET = 95.2%). A higher proportion of patients discontinuing NTZ due to increased PML risks switched to Mod DMT (72.7%) compared with HET (60.1%) ( $p = 0.019$ ), which was consistent with the increased proportion of patients who switched to Mod DMT (62.6%) vs HET (47.0%) due to JC virus antibody seropositivity at any time ( $p = 0.027$ ). The mean washout duration between groups was similar and relatively short (Mod DMT = 1.4 months, HET = 1.8 months;  $p = 0.340$ ), reducing the risk of disease reactivation that otherwise would have posed an additional confounder. Duration of NTZ treatment did not differ between our cohorts. As expected, the proportion with baseline disease activity, measured via relapses and new T2 and/or GdE lesions, before starting NTZ was numerically higher compared with disease activity while on NTZ (table 1).

### Propensity score model

The PS model was built using demographics and baseline clinical, radiographic, laboratory, and PRO characteristics summarized in table 1. Missing covariate data did not considerably change the overall balance of covariates after PS weighting. The model correctly assigned higher PS to the Mod DMT group compared with the HET group (figure e-1, links.lww.com/CPJ/A162), given that the logistic regression model was calculated to determine the likelihood of switching from NTZ to the former treatment paradigm. Before ATT weighting, the treatment groups were not balanced well with at least half of the covariates falling outside of the 10% absolute standardized difference range. Furthermore, the absolute value of the standardized difference of the linear PS comparing Mod DMT with HET was 91.2%, which was considerably greater than the 50% standard previously recommended by Rubin.<sup>36</sup> Therefore, we determined that PS adjustment was warranted to account for indication bias before making conclusions on differences in treatment effects.

PS weighting balanced the two treatment groups effectively with only 5 covariates obtaining absolute standardized differences >10% (figure e-2, links.lww.com/CPJ/A162). In a double robust approach, PS weighting also produced a similar linear PS distribution with a standardized difference of 17.2%, which was sufficiently within the 50% standard.

### Outcome estimates by 6-month follow-up

To estimate the effectiveness of switching from NTZ to a Mod DMT vs HET on early MS disease activity, we compared inflammatory disease outcomes (e.g., relapse, MRI activity, and absence of disease activity) within 6 months of NTZ discontinuation. Unadjusted and postweighting outcomes are summarized in tables 2 and 3. By 6 months, 11.7% of Mod

**Table 1** Baseline characteristics of NTZ switchers to Mod DMT vs HET<sup>a</sup>

	Moderate efficacy, n = 270		High efficacy, n = 130		p Value
	n or mean	% or SD	n or mean	% or SD	
<b>Demographics</b>					
Age at diagnosis (years, SD)	33.3	9.0	32.1	9.6	0.228
Age at NTZ discontinuation (years, SD)	42.5	9.9	42.2	10.8	0.778
Sex (female)	182	67.4%	88	67.7%	1.000
Race					0.079
White	224	86.2%	92	75.4%	
Black	32	12.3%	26	21.3%	
Other	4	1.6%	4	3.3%	
<b>Comorbidities</b>					
Tobacco smoking	72	26.7%	29	22.3%	0.414
Asthma	27	10.0%	17	13.1%	0.072
Cancer	11	4.1%	1	0.8%	0.133
COPD	4	1.5%	0	0.0%	0.391
Diabetes mellitus	24	8.9%	8	6.2%	0.455
Hyperlipidemia	45	16.7%	10	7.7%	0.022 <sup>b</sup>
Hypertension	57	21.1%	17	13.1%	0.072
<b>Disease history</b>					
Disease duration (years, SD)	17.1	8.6	15.1	8.9	0.041 <sup>b</sup>
Relapsing-remitting MS at disease onset	255	95.9%	120	95.2%	0.422
Disease course at NTZ discontinuation					0.021 <sup>b</sup>
Relapsing-remitting	199	74.8%	109	83.8%	
Primary progressive	2	0.8%	3	2.3%	
Progressive relapsing	10	3.8%	0	0.0%	
Secondary progressive	55	20.7%	18	13.8%	
No. of previous DMTs (number, SD)	2.9	1.6	3.0	1.5	0.443
Interferon	229	84.8%	95	73.1%	0.037 <sup>b</sup>
Glatiramer	115	42.6%	55	42.3%	1.000
Fingolimod	10	3.7%	23	17.7%	<0.001 <sup>b</sup>
Dimethyl fumarate	6	2.2%	31	24.0%	<0.001 <sup>b</sup>
Teriflunomide	2	0.7%	5	3.8%	0.070
Mitoxantrone	6	2.2%	0	0.0%	0.203
Other immunosuppressive	30	11.1%	10	5.9%	0.065
NTZ infusions, mean (range)	35 (1–93)	N/A	28 (1–65)	N/A	0.142
<b>Reason for NTZ discontinuation</b>					
Breakthrough disease	40	14.8%	24	18.5%	0.776
Intolerance	53	19.6%	31	23.8%	0.504
NTZ risks (PML)	196	72.7%	78	60.1%	0.019 <sup>b</sup>

Continued

**Table 1** Baseline characteristics of NTZ switchers to Mod DMT vs HET<sup>a</sup> (continued)

	Moderate efficacy, n = 270		High efficacy, n = 130		p Value
	n or mean	% or SD	n or mean	% or SD	
<b>DMT washout (mean, SD)</b>	1.4	5.5	1.8	4.5	0.340
<b>Labs</b>					
<b>JCV antibody status at NTZ discontinuation</b>					
<b>Negative</b>	68	35.8%	59	50.4%	0.027 <sup>b</sup>
<b>Positive</b>	119	62.6%	55	47.0%	
<b>Indeterminate</b>	3	1.6%	3	2.6%	
<b>ALC at NTZ discontinuation (×10<sup>9</sup>/L; mean, SD)</b>	3.2	1.1	3.2	1.0	0.739
<b>Disease activity</b>					
<b>Relapse before NTZ initiation</b>	103	40.1%	56	48.3%	0.171
<b>Relapse during NTZ treatment</b>	13	4.8%	7	5.4%	1.000
<b>Brain MRI before NTZ initiation</b>					
<b>GdE lesions</b>	102	44.5%	46	46.0%	0.901
<b>New T2 lesions</b>	85	37.1%	45	46.9%	0.130
<b>Brain MRI 6 months before NTZ discontinuation</b>					
<b>GdE lesions</b>	3	3.2%	0	0.0%	0.436
<b>New T2 lesions</b>	2	2.1%	0	0.0%	0.663
<b>Objective measures</b>					
<b>T25FW (s, SD)</b>	9.1	9.0	7.3	3.9	0.086
<b>Ambulation assistance</b>				0.175	
<b>None</b>	174	69.9%	88	79.3%	
<b>Unilateral</b>	26	10.4%	8	7.2%	
<b>Bilateral</b>	38	15.3%	9	8.1%	
<b>Wheelchair</b>	11	4.4%	6	5.4%	
<b>9-HPT dominant (mean sec, SD)</b>	30.5	16.9	26.4	9.3	0.099
<b>Patient-reported outcomes</b>					
<b>MS performance scale</b>	15.0	7.7	14.5	8.5	0.694
<b>PHQ-9 score, depressed</b>	69	43.7%	27	38.0%	0.512

Abbreviations: 9-HPT = 9-hole peg test; ALC = absolute lymphocyte count; GdE = gadolinium enhancing; HET = high-efficacy therapy; JCV = JC virus; Mod = moderate-efficacy DMT; NTZ = natalizumab; PHQ-9 = Patient Health Questionnaire-9; T25FW = timed 25-foot walk; MS = multiple sclerosis. NTZ discontinuation due to breakthrough disease is defined as NTZ cessation due to clinical relapses, new MRI activity, or progression of disability. PHQ-9 score, depressed defined as PHQ-9 score ≥10.


<sup>a</sup> Unless otherwise specified in the table, baseline disease characteristics defined as the time period within 12 months of NTZ initiation.

<sup>b</sup> Statistically significant p value (alpha = 0.05).

DMT-treated patients experienced a clinical relapse vs 8.7% of HET-treated patients with a PS-adjusted OR = 1.36 (95% confidence interval [CI] [0.72–1.66],  $p = 0.724$ ). In an ITT model, MRI disease activity favored those who switched to HET (OR = 1.68,  $p = 0.068$ ) but did not reach statistical significance. In a sensitivity analysis including only patients on treatment, those treated with Mod DMT had higher MRI

disease activity (OR = 2.59, 95% CI [1.09–3.87],  $p = 0.037$ ), GdE lesions (OR = 3.37, 95% CI [1.45–4.68],  $p = 0.007$ ), and new T2-hyperintense lesions (OR = 2.18, 95% CI [1.10–4.01],  $p = 0.029$ ). Furthermore, of those who had available clinical and MRI data by 6-month follow-up (Mod DMT n = 238, HET n = 109), patients switching from NTZ to Mod DMT had lower likelihood of achieving absence of disease activity (61.3%)

**Figure 1** Study flow diagram



At 24-month follow-up, 270 patients switched from NTZ to a Mod DMT (fingolimod and dimethyl fumarate), and 130 patients switched to HET (ocrelizumab, rituximab, and alemtuzumab). The majority of patients discontinued NTZ due to increased PML risks, of which a greater proportion switched to Mod DMT vs HET. Low (efficacy) DMT: glatiramer acetate, interferon beta, teriflunomide. Other IS: azathioprine, mycophenolate mofetil, cyclophosphamide, pulse methylprednisolone, and pulse IVIG. DMT = disease-modifying therapy; HET = high-efficacy therapy; IS = immunosuppressive therapy; Mod = moderate-efficacy DMT; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy.

compared with those who switched to HET (80.7%) (OR = 0.42, 95% CI [0.23–0.76],  $p = 0.004$ ).

### Outcome estimates by 24-month follow-up

To determine the durability of treatment effect on inflammatory disease activity and disability progression, we assessed 24-month outcomes in NTZ switchers to Mod DMT vs HET (tables 2 and 3). By 24 months, 13.3% of Mod DMT patients had a clinical relapse vs 10.0% of HET patients. Mod DMT patients had 36 relapses over 171.4 patient-years of treatment with ARR = 0.21 (95% CI = 0.07–0.39). HET patients had 13 relapses over 118.2 patient-years of treatment with ARR = 0.11 (95% CI = 0.05–0.42). After PS weighting, there was no difference in the ARR (ARR ratio = 1.44, 95% CI [0.69–1.59],  $p = 0.334$ ). The mean time to first relapse was 3.2 months for Mod DMT compared with 4.4 months for HET. Although survival outcomes favored HET, no difference was found in time to first relapse between groups over the first 24 months of treatment (HR = 2.12, 95% CI [0.87–5.17],  $p = 0.090$ ) (figure 2).

In an ITT model, among all patients with available MRI data by 24-month follow-up (Mod DMT  $n = 252$ , HET  $n = 126$ ), 25.4% of patients on Mod DMT demonstrated MRI activity vs 11.9% on HET (OR = 2.43, 95% CI [1.08–3.93],  $p = 0.039$ ). A sensitivity analysis comparing only patients on treatment showed similar findings. Furthermore, patients treated with Mod DMT had higher odds of GdE lesions (OR = 1.99, 95% CI [1.12–2.73],  $p = 0.022$ ) and new T2-hyperintense lesions (OR = 2.15, 95% CI [1.18–3.01],  $p = 0.011$ ) with similar findings in a sensitivity analysis only comparing patients on treatment (tables 2 and 3). Patients who switched to Mod DMT also experienced earlier time to first GdE lesion compared with HET (HR = 6.67, 95% CI [2.06–9.16],  $p = 0.002$ ) (figure 3). An additional sensitivity analysis comparing

inflammatory disease outcomes stratified by reason for discontinuation—breakthrough disease and safety risks—also showed similar results to the entire cohort, although comparative increased disease activity in the Mod DMT group appeared to be driven by NTZ switchers due to breakthrough disease (table 4).

Of patients with available on-treatment clinical and MRI outcome data by 24 months (Mod DMT  $n = 127$ , HET  $n = 92$ ), NTZ switchers to Mod DMT had lower likelihood of absence of disease activity (63.7%) vs HET (80.4%) (OR = 0.41, 95% CI [0.21–0.71],  $p = 0.004$ ). Using surrogate markers of disability progression, NTZ switchers to Mod DMT experienced higher odds of 20% worsening of the T25FW (OR = 1.83, 95% CI [1.06–3.02],  $p = 0.043$ ) and 20% worsening of the 9-HPT (OR = 1.81, 95% CI [1.05–3.56],  $p = 0.044$ ). There were no cases of PML or other serious opportunistic infections reported in either cohort.

### Discussion

NTZ is a high-efficacy DMT indicated for relapsing forms of MS, for which long-term use in clinical practice is limited by potential safety risks, including PML. The risk is particularly high in patients who (1) have a high anti-JC virus antibody index, (2) had NTZ exposure longer than 24 months, and (3) had previous exposure to immunosuppressive therapies.<sup>4,5</sup> In the current neurotherapeutic landscape of multiple available DMTs with various mechanisms of action and effectiveness and safety profiles, it is possible to lower these PML risks by switching patients to another therapy. However, an additional risk of disease reactivation occurs upon NTZ interruption. After NTZ discontinuation, the time to return of  $\alpha 4\beta 1$ -integrin antigen saturation to values found in untreated patients likely

**Table 2** Summary of unadjusted effectiveness outcomes of NTZ switchers to Mod DMT vs HET

	Moderate efficacy, n = 270		High efficacy, n = 130		p Value
	n	% or SD	n	% or SD	
<b>6-month outcomes</b>					
Clinical relapse (no. of patients)	31	11.7%	11	8.7%	0.462
Relapses per patient (mean, SD)	0.12	0.32	0.09	0.28	0.364
MRI available for review (intention to treat)	219	81.1%	107	82.3%	0.824
MRI activity (GdE + new T2 lesions)	47	21.5%	12	11.2%	0.054
GdE lesions	37	16.9%	11	10.3%	0.285
New T2 lesions	46	21.0%	15	14.0%	0.127
MRI available for review (on treatment)	184	68.1%	94	72.6%	0.133
MRI activity (GdE + new T2 lesions)	46	25.0%	8	8.5%	0.039 <sup>b</sup>
GdE lesions	30	16.3%	2	2.1%	0.014 <sup>b</sup>
New T2 lesions	39	21.4%	8	8.5%	0.042 <sup>b</sup>
Absence of disease activity <sup>a</sup>	146/238	61.3%	88/109	80.7%	0.005 <sup>b</sup>
<b>24-month outcomes</b>					
Clinical relapse (no. of patients)	36	13.3%	13	10.0%	0.122
Relapses per patient (mean, SD)	0.14	0.28	0.06	0.26	0.364
MRI available for review (intention to treat)	252	93.3%	126	96.9%	0.244
MRI activity (GdE + new T2 lesions)	64	25.4%	15	11.9%	0.012 <sup>b</sup>
GdE lesions	44	17.5%	11	8.7%	0.028 <sup>b</sup>
New T2 lesions	72	28.6%	19	15.1%	0.021 <sup>b</sup>
MRI available for review (on treatment)	136	50.4%	81	62.3%	0.011 <sup>b</sup>
MRI activity (GdE + new T2 lesions)	26	19.1%	8	9.9%	0.029 <sup>b</sup>
GdE lesions	24	17.6%	6	7.4%	0.013 <sup>b</sup>
New T2 lesions	28	20.6%	8	9.9%	0.010 <sup>b</sup>
Absence of disease activity <sup>a</sup>	81/127	63.7%	74/92	80.4%	0.006 <sup>b</sup>
<b>Measures of neurologic disability</b>					
T25FW (mean sec, SD)	8.26	7.21	6.01	5.21	0.032 <sup>b</sup>
20% worsening of T25FW	113/203	55.6%	38/94	40.2%	0.045 <sup>b</sup>
9-HPT dominant (mean sec, SD)	24.93	10.65	21.36	10.11	0.039 <sup>b</sup>
20% worsening of 9-HPT	103/189	54.5%	37/83	44.6%	0.048 <sup>b</sup>

Abbreviations: 9-HPT = 9-hole peg test; DMT = disease-modifying therapy; GdE = gadolinium enhancing; HET = highly effective therapy; Mod = moderate; T25FW = timed 25-foot walk.

<sup>a</sup> Absence of disease activity defined as absence of clinical relapses + absence of MRI activity (GdE lesions and/or new T2 lesions).

<sup>b</sup> Statistically significant p value (alpha = 0.05).

vary across individuals and is predictive of the risk of GdE lesion occurrence and rebound disease.<sup>8,37,38</sup>

Consensus is currently lacking on DMT switching strategies after NTZ withdrawal and is primarily based on single-arm investigations with variable outcomes, a few small comparative

effectiveness studies, or expert opinion. Further observational studies are thus warranted to compare the effectiveness of post-NTZ sequencing strategies to guide decision making in clinical practice. To fill this knowledge gap, we conducted a real-world PS-adjusted study comparing patients switching from NTZ to Mod DMT vs HET in a clinical practice cohort. We investigated

**Table 3** Unadjusted and adjusted effectiveness outcomes of NTZ switchers to Mod DMT vs HET

	Unadjusted			Propensity adjusted		
	Odds or hazards ratio	95% CI	p Value	Odds or hazards ratio	95% CI	p Value
<b>6-month outcomes</b>						
<b>Proportion with clinical relapse</b>	1.32	0.66–2.03	0.764	1.36	0.72–1.66	0.724
<b>MRI disease activity (intention-to-treat)</b>						
<b>MRI activity (GdE + new T2 lesions)</b>	1.72	0.92–2.85	0.077	1.68	0.94–2.13	0.068
<b>GdE lesions</b>	1.61	0.76–3.39	0.281	1.63	0.83–2.69	0.202
<b>New T2 lesions</b>	1.57	0.81–3.05	0.200	1.58	0.84–2.91	0.189
<b>MRI disease activity (on-treatment)</b>						
<b>MRI activity (GdE + new T2 lesions)</b>	2.63	1.11–4.19	0.032 <sup>b</sup>	2.59	1.09–3.87	0.037 <sup>b</sup>
<b>GdE lesions</b>	3.35	1.42–4.85	0.006 <sup>b</sup>	3.37	1.45–4.68	0.007 <sup>b</sup>
<b>New T2 lesions</b>	2.14	1.08–4.12	0.038 <sup>b</sup>	2.18	1.10–4.01	0.029 <sup>b</sup>
<b>Absence of disease activity<sup>a</sup></b>	0.52	0.34–0.82	0.005 <sup>b</sup>	0.42	0.23–0.76	0.004 <sup>b</sup>
<b>24-month outcomes</b>						
<b>Annualized relapse rate (ARR) ratio</b>	1.43	0.72–1.96	0.423	1.44	0.69–1.59	0.334
<b>Proportion with clinical relapse</b>	1.40	0.68–2.88	0.389	1.36	0.62–1.78	0.711
<b>Time to first relapse (months, mean)</b>	1.74	0.84–4.23	0.126	2.12	0.87–5.17	0.090
<b>MRI disease activity (intent to treat)</b>						
<b>MRI activity (GdE + new T2 lesions)</b>	2.36	1.07–4.12	0.038 <sup>b</sup>	2.43	1.08–3.93	0.039 <sup>b</sup>
<b>GdE lesions</b>	1.89	1.08–3.24	0.037 <sup>b</sup>	1.99	1.12–2.73	0.022 <sup>b</sup>
<b>New T2 lesions</b>	2.02	1.09–3.03	0.018 <sup>b</sup>	2.15	1.18–3.01	0.011 <sup>b</sup>
<b>MRI disease activity (on treatment)</b>						
<b>MRI activity (GdE + new T2 lesions)</b>	2.72	1.16–3.13	0.032 <sup>b</sup>	2.54	1.18–3.07	0.021 <sup>b</sup>
<b>GdE lesions</b>	3.59	1.49–5.48	0.006 <sup>b</sup>	3.62	1.56–5.21	0.005 <sup>b</sup>
<b>New T2 lesions</b>	2.14	1.08–4.12	0.033 <sup>b</sup>	2.23	1.17–3.88	0.024 <sup>b</sup>
<b>Time to first GdE lesion (months, mean)</b>	5.23	2.12–8.64	0.003 <sup>b</sup>	6.67	2.06–9.16	0.002 <sup>b</sup>
<b>Absence of disease activity<sup>a</sup></b>	0.55	0.28–0.77	0.004 <sup>b</sup>	0.41	0.21–0.71	0.004 <sup>b</sup>
<b>Measures of neurologic disability</b>						
<b>20% worsening of T25FW</b>	1.78	1.03–3.21	0.045 <sup>b</sup>	1.83	1.06–3.02	0.043 <sup>b</sup>
<b>20% worsening of 9-HPT</b>	1.76	1.01–3.68	0.047 <sup>b</sup>	1.81	1.05–3.56	0.044 <sup>b</sup>

Abbreviations: 9-HPT = 9-hole peg test; CI = confidence interval; DMT = disease-modifying therapy; GdE = gadolinium enhancing; HET = highly effective therapy; Mod = moderate; NTZ = natalizumab; T25FW = timed 25-foot walk.

<sup>a</sup> Absence of disease activity defined as absence of clinical relapses + absence of MRI activity (GdE lesions and/or new T2 lesions).


<sup>b</sup> Statistically significant p value (alpha = 0.05).

6-month time points to determine the early comparative effectiveness of NTZ switch to one of two treatment strategies and 24-month time points to capture the durability of the new treatment's effect.

Overall, disease activity remained low at 6-month and 24-month follow-up in both post-NTZ treatment arms, relative to the 12-month pre-NTZ period. Numerically, there was a signal

for increased disease activity post-NTZ across both groups relative to the time on treatment, but it did not supersede that of the pre-NTZ period. Therefore, in our population, patients did not experience rebound disease—putatively related to an immune reconstitution inflammatory syndrome-like phenomenon.<sup>39</sup> Likely, the low disease activity was related to two different mechanisms in our study population: (1) a short washout duration (mean <2 months) across both treatment

**Figure 2** Kaplan-Meier plot of relapse-free status through 24-month follow-up




groups and (2) a form of inflammatory protection by switching to an alternative DMT of at least moderate efficacy. The French TYSEDMUS study ( $n = 4,055$ ) showed that 37.1% of patients who discontinued NTZ experienced a relapse within 12 months of drug interruption, mainly occurring between 3 and 5 months of NTZ cessation. Similarly, this study did not observe rebound disease activity with a pre-NTZ ARR = 1.99 and post-NTZ ARR = 0.65.<sup>9</sup> On the other hand, a smaller study investigating the effects of NTZ interruption showed that the cumulative probability of rebound disease activity was 39% and mostly occurred between 3 and 9 months after NTZ cessation, independently of an alternative DMT.<sup>6</sup> These reported differences in relapse rates and risk of rebound disease upon NTZ cessation are likely related to variable use and sequencing of DMTs across centers and the restrictive availability of NTZ in France to patients with very active disease.

Various studies previously demonstrated the benefit of switching to an alternative DMT following NTZ discontinuation to reduce the risk of rebound disease. In 1 study, Villaverde-Gonzalez et al. showed that 71.4% of patients remained relapse-free after switching from NTZ to one of the platform DMTs. Furthermore, 62.5% of patients experienced no radiologic activity 12 months after NTZ cessation.<sup>40</sup> However, this study was limited by a small sample size and the use of less effective DMTs (e.g., glatiramer acetate and interferon beta) post-NTZ, which are suspected to have limitations in

preventing rebound disease.<sup>19–21</sup> Patients switching to more efficacious therapies may have better disease control.<sup>11,13–17,22,23</sup> For instance, a large study ( $n = 536$ ) showed that patients switching from NTZ to fingolimod experienced only a small rise in the relapse rate (ARR = 0.38) relative to the period while on NTZ (ARR = 0.26,  $p = 0.002$ ).<sup>41</sup>

Our PS analysis demonstrated no differences in clinical relapses between NTZ switchers to Mod DMT vs HET, although it numerically favored HET. The mean time to first clinical relapse (3–5 months) observed in our patient population was consistent with the natural course of drug elimination and what was previously reported in a number of smaller studies.<sup>6,38</sup> Although there were no differences across early MRI disease activity end points in an ITT model, our sensitivity analysis on-treatment at 6-month follow-up and cumulative MRI disease activity over 24 months demonstrated lower effectiveness in NTZ switchers to Mod DMT compared with HET. Data in patients switching from NTZ to other HET are scarce. However, 1 comparative effectiveness study favored rituximab ( $n = 114$ ) over fingolimod ( $n = 142$ ) in patients discontinuing NTZ in relation to relapses (rituximab 1.8%, fingolimod 17.6%) and GdE lesions (0.9% vs 16.2%) at 1.5 years.<sup>22</sup> These data are consistent with those reported in the current investigation. Another small observational study ( $n = 16$ ) investigating patients who switched from NTZ to alemtuzumab had no relapses, MRI activity, or increased EDSS scores.<sup>23</sup> These data

**Figure 3** Kaplan-Meier plot of GdE lesion-free status through 24-month follow-up



Kaplan-Meier survival analysis showed earlier time to first GdE lesion in patients switching from NTZ to moderate- vs high-efficacy DMT. DMT = disease-modifying therapy.

collectively suggest that rituximab and alemtuzumab are favorable options for post-NTZ therapy.

In a subgroup comparative effectiveness analysis stratified by reason for NTZ discontinuation, increased MRI activity in the Mod DMT group was driven by patients who withdrew from NTZ due to breakthrough disease. A similar finding, reporting on relapse rates, was observed in a study by Jokubaitis et al.<sup>14</sup> that reported that 30% of patients with disease activity on NTZ relapsed within the first 6 months of transitioning onto fingolimod (RR = 0.001–0.13).

Other predictors of disease reactivation following NTZ withdrawal were described. Independent predictors of time to first clinical relapse in NTZ switchers to fingolimod in the Jokubaitis et al.<sup>14</sup> study were the number of clinical relapses within the previous 6 months (HR = 1.59;  $p = 0.002$ ) and washout duration of 2–4 months compared with no washout at all (HR = 2.10;  $p = 0.041$ ). A smaller French prospective study investigating the effects of switching from NTZ to fingolimod similarly showed a lower risk of relapse (OR = 0.23;  $p = 0.001$ ) during a shorter washout period <3 months and with less disease activity before NTZ initiation ( $p = 0.03$ ).<sup>11</sup>

Approximately 20% of patients relapsed during the first 6 months of fingolimod treatment in a previous study.<sup>11</sup> In

contrast, our patient population experienced a lower risk of clinical relapses within the first 6 months of therapy when switching from NTZ to Mod DMT (11.7%) and an even lower risk when transitioning onto another HET (8.7%). This difference was likely related to the shorter mean washout period in our patient population (1.6 months) vs a mean of 4.3 months in the French study. It is unlikely that the inclusion of dimethyl fumarate in the Mod DMT cohort in our investigation yielded a considerable difference in findings relative to other studies reporting on the effectiveness of NTZ to fingolimod transition. However, if the addition of dimethyl fumarate was a differential factor, the anticipation would be for a greater number of relapses in our cohort (rather than fewer), given that no observational studies to date have demonstrated superior effectiveness of dimethyl fumarate compared with fingolimod. Similarly, another study showed that the ARR 1 year after NTZ to dimethyl fumarate transition was lower in those with a washout duration  $\leq 3$  months vs  $> 3$  months (rate ratio 0.49, 95% CI [0.26–0.90]).<sup>15</sup> Overall, published studies collectively demonstrated that a washout period <3 months between NTZ and fingolimod or dimethyl fumarate is important in preventing disease reactivation.

In this study, the treating providers likely started patients on NTZ they thought were at highest risk of disease activity. Thus, the fact that individuals in the Mod group fared worse (despite

**Table 4** Unadjusted and adjusted effectiveness outcomes of NTZ switchers to Mod DMT vs HET by 24-month follow-up, stratified by reason for NTZ discontinuation

	Unadjusted			Propensity adjusted		
	Odds or hazards ratio	95% CI	p Value	Odds or hazards ratio	95% CI	p Value
<b>NTZ discontinuation due to breakthrough disease<sup>b</sup></b>						
Proportion with clinical relapse	1.64	0.89–4.92	0.083	1.71	0.95–4.74	0.061
<b>MRI disease activity (intention-to-treat)</b>						
MRI activity (GdE + new T2 lesions)	1.79	0.98–5.23	0.057	1.87	1.01–5.17	0.049 <sup>c</sup>
GdE lesions	1.83	0.99–5.44	0.053	1.94	1.06–5.68	0.043 <sup>c</sup>
New T2 lesions	1.81	0.98–5.03	0.055	1.89	1.02–5.24	0.047 <sup>c</sup>
<b>MRI disease activity (on-treatment)</b>						
MRI activity (GdE + new T2 lesions)	2.74	1.18–6.32	0.028 <sup>c</sup>	2.68	1.10–6.33	0.034 <sup>c</sup>
GdE lesions	3.57	1.48–7.23	0.005 <sup>c</sup>	3.42	1.49–7.16	0.006 <sup>c</sup>
New T2 lesions	2.23	1.09–6.87	0.034 <sup>c</sup>	2.31	1.09–6.21	0.027 <sup>c</sup>
Absence of disease activity <sup>a</sup>	0.48	0.32–0.83	0.004 <sup>c</sup>	0.39	0.21–0.89	0.003 <sup>c</sup>
<b>NTZ discontinuation due to safety risks<sup>b</sup></b>						
Proportion with clinical relapse	1.38	0.63–3.93	0.382	1.33	0.62–3.18	0.823
<b>MRI disease activity (intention-to-treat)</b>						
MRI activity (GdE + new T2 lesions)	1.66	0.94–5.33	0.123	1.68	0.94–4.26	0.131
GdE lesions	1.72	0.97–4.89	0.092	1.73	0.97–4.54	0.087
New T2 lesions	1.63	0.91–4.21	0.134	1.65	0.95–4.72	0.098
<b>MRI disease activity (on-treatment)</b>						
MRI activity (GdE + new T2 lesions)	2.01	1.05–4.29	0.043 <sup>c</sup>	2.08	1.05–5.26	0.043 <sup>c</sup>
GdE lesions	2.45	1.12–5.87	0.041 <sup>c</sup>	2.47	1.14–6.01	0.039 <sup>c</sup>
New T2 lesions	2.16	1.07–5.03	0.042 <sup>c</sup>	2.21	1.08–4.58	0.041 <sup>c</sup>
Absence of disease activity <sup>a</sup>	0.61	0.32–0.89	0.012 <sup>c</sup>	0.62	0.33–0.85	0.011 <sup>c</sup>

Abbreviations: CI = confidence interval; DMT = disease-modifying therapy; GdE = gadolinium enhancing; HET = high-efficacy therapy; Mod = moderate-efficacy therapy; NTZ = natalizumab.

<sup>a</sup> Absence of disease activity defined as absence of clinical relapses + absence of MRI activity (GdE lesions and/or new T2 lesions).

<sup>b</sup> NTZ discontinuation due to breakthrough disease (Mod DMT n = 40, HET n = 24); NTZ discontinuation due to safety risks (Mod DMT n = 196, HET n = 78).

<sup>c</sup> Statistically significant p value (alpha = 0.05).

likely having less aggressive disease) would support the need to transition most patients to HET after NTZ. The current investigation was limited by various factors. First, our PS model could not adjust for unmeasured covariates or residual biases. To reduce the risk of hidden bias, we included a comprehensive list of covariates believed to be important and representative of those factors essential in determining treatment allocation following NTZ discontinuation. Other limitations inherent in observational studies included the retrospective nature of the investigation, missing data (e.g., radiologic and objective measures of disability progression), and the potential for recall bias in patient-reported relapses. However, the frequency of established visits at our centers (on average every 3–6 months)

and the requirement for relapse confirmation by the treating clinician before inclusion into the study accounted for the latter concern. We do not routinely assess EDSS scores during follow-up visits; therefore, surrogate measures of disability progression including 20% worsening of the T25FW and 9-HPT were reported.<sup>32</sup> Our study is also limited in that it was conducted at two tertiary referral MS centers, which likely differ in patient population and treatment practices compared with other community centers. Despite these limitations, this comprehensive real-world study provides clinical insights into the comparative effectiveness of switching from NTZ to alternative treatment strategies that are increasingly used in routine practice.

## Conclusion

The current study provides real-world clinical insights into DMT switching patterns following NTZ discontinuation. Patients switching from NTZ to Mod DMT vs HET are at relatively increased risk of disease activity within the first 6 months of NTZ withdrawal, which is sustained at 24 months, yielding greater disability progression. The current study also demonstrates that switching to a DMT of at least moderate efficacy following NTZ discontinuation is effective in reducing the risk of rebound disease when restricting the washout period to <3 months, particularly in those switching to HET. Thus, these data suggest that an HET should be considered in the appropriate clinical setting when transitioning a patient off of NTZ, especially when due to breakthrough disease. A larger, multicenter study investigating the short- and long-term effects of post-NTZ DMT sequencing is planned to improve upon the external validity of the current findings.

## Acknowledgment

The authors thank the patients treated at the Cleveland Clinic Lou Ruvo Center for Brain Health and Cleveland Clinic Mellen Center.

## Study funding

This study received partial funding support from the Sheila and Eric Samson Foundation.

## Disclosure

C.M. Hersh has received speaking and consulting fees from Genzyme, Genentech, EMD Serono, Novartis, and Biogen and has received research support paid to her institution from Biogen, Genentech, and PCORI. H. Harris reports no disclosures. D. Conway has received research support paid to his institution from Novartis and the National Multiple Sclerosis Society and has received personal compensation for consulting from Novartis and Tanabe Laboratories. L.H. Hua has received speaking and consulting fees from Biogen, Genzyme, Genentech, Novartis, Celgene, and EMD Serono. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](http://Neurology.org/cp).

## Publication history

Received by *Neurology: Clinical Practice* September 23, 2019. Accepted in final form December 9, 2019.

## Appendix Authors

Name	Location	Contribution
<b>Carrie M. Hersh, DO, MSc</b>	Cleveland Clinic Lou Ruvo Center for Brain Health	Drafted and revised the manuscript for intellectual content and contributed to the study concept, design, acquisition, analysis, and interpretation of the data
<b>Haleigh Harris, BA</b>	Cleveland Clinic Lou Ruvo Center for Brain Health	Contributed to the data acquisition

## Appendix (continued)

Name	Location	Contribution
<b>Devon Conway, MD</b>	Cleveland Clinic Mellen Center	Contributed to the study concept, interpretation of the data, and revision of the manuscript
<b>Le H. Hua, MD</b>	Cleveland Clinic Lou Ruvo Center for Brain Health	Contributed to the study concept, interpretation of the data, and revision of the manuscript

## References

- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med* 2006;354:899–910.
- Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. *Neurology* 2007;68:1390–1401.
- Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. *Autoimmun Rev* 2017;16:658–665.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. *N Engl J Med* 2012;366:1870–1880.
- Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. *Ann Neurol* 2014;76:802–812.
- Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2014;85:1038–1040.
- O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. *Neurology* 2011;76:1858–1865.
- Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. *Neurology* 2008;70:1150–1151.
- Papeix C, Vukusic S, Casey R, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. *Neurol Neuroimmunol Neuroinflamm* 2016;3:e297.
- Sellner J, Rommer PS. A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. *Autoimmun Rev* 2019;18:255–261.
- Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. *JAMA Neurol* 2014;71:436–441.
- Fox RJ, Cree BAC, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab interruption study. *Neurology* 2014;82:1491–1498.
- Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. *Neurology* 2015;85:29–39.
- Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology* 2014;82:1204–1211.
- Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). *Mult Scler Relat Disord* 2018;22:27–34.
- Calabrese M, Pitteri M, Farina G, et al. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. *J Neurol Neurosurg Psychiatry* 2017;88:1073–1078.
- Zurawski J, Flinn A, Sklover L, Sloane JA. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. *J Neurol* 2016;263:1511–1517.
- Edwards KR, Kamath V, O'Connor J. Switching From Natalizumab to Teriflunomide in Multiple Sclerosis Patients Who Have Received Natalizumab for More Than 12 Months. Abstract presented at 2014 CMSC ACTRIMS Annual Meeting; May 29, 2014; Dallas, TX. Available at: [cmsc.confex.com/cmsc/2014/webprogram/Paper2464.html](http://cmsc.confex.com/cmsc/2014/webprogram/Paper2464.html). Accessed July 16, 2019.
- Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. *BMC Neurol* 2013;13:101.
- Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. *J Neurol* 2011;258:1665–1669.
- Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. *Eur J Neurol* 2013;20:87–94.
- Mancinelli CR, Scarpazza C, Santuccio G, et al. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help? *Neurol Sci* 2018;39:965–966.
- Malucchi S, Capobianco M, Lo Re M, et al. High-risk PML patients switching from natalizumab to alemtuzumab: an observational study. *Neurol Ther* 2017;6:145–152.
- Rosenbaum R, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;70:41–55.
- Hersh CM, Love TE, Bandyopadhyay A, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. *Mult Scler J Exp Transl Clin* 2017;3:2055217317715485.
- Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. *Mult Scler J Exp Transl Clin* 2017;3:2055217317725102.
- Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. *Neurol Clin Pract* 2018;8:292–301.

28. Fox RJ, Chan A, Zhang A, et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. *Curr Med Res Opin* 2017;33:175–183.
29. Prosperini L, Lucchini M, Haggiag S, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis. A Real-World Propensity Score-Matched Study. *Neurology* 2018; 91:e153–e161.
30. Wicks P, Rasouliyan L, Katic B, Nafees B, Flood E, Sasané R. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. *BMC Res Notes* 2016;9:434.
31. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. *Mult Scler* 2006;8:359–365.
32. Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. *Mult Scler* 2006;12:594–598.
33. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16:606–613.
34. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. *Neurology* 1999;52:63–70.
35. Team RC. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2014.
36. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. *Health Serv Outcomes Res Methodol* 2001;2: 169–188.
37. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. *Neurology* 2017;89: 1584–1593.
38. Cree B, de Seze J, Fox R, et al. Natalizumab effects during a 6 month dose interruption: relationship of pharmacokinetic (PK), pharmacodynamic (PD) and MRI measurement. *Neurology* 2013;80:S41.003.
39. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. *Arch Neurol* 2011;68:186–191.
40. Villaverde-Gonzalez R, Gracia Gil J, Perez Sempere A, et al. Observational study of switching from natalizumab to immunomodulatory drugs. *Eur Neurol* 2017;77: 130–136.
41. Comi G, Gold R, Dahlke F, et al. Relapses in patients treated with fingolimod after previous exposure to natalizumab. *Mult Scler* 2015;21:786–790.

# Neurology® Clinical Practice

## Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice

Carrie M. Hersh, Haleigh Harris, Devon Conway, et al.  
*Neurol Clin Pract* published online February 12, 2020  
DOI 10.1212/CPJ.0000000000000809

**This information is current as of February 12, 2020**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://cp.neurology.org/content/early/2020/02/12/CPJ.0000000000000809.full.html">http://cp.neurology.org/content/early/2020/02/12/CPJ.0000000000000809.full.html</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://cp.neurology.org/content/early/2020/02/12/CPJ.0000000000000809.full.html##otherarticles">http://cp.neurology.org/content/early/2020/02/12/CPJ.0000000000000809.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Multiple sclerosis</b> <a href="http://cp.neurology.org/cgi/collection/multiple_sclerosis">http://cp.neurology.org/cgi/collection/multiple_sclerosis</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://cp.neurology.org/misc/about.xhtml#permissions">http://cp.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://cp.neurology.org/misc/addir.xhtml#reprintsus">http://cp.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Clin Pract* is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.

